On the one hand, β-TrCP activates NF-κB signaling by degrading IκB (NF-κB inhibitors), promotes the release of pro-inflammatory factors (such as TNF-α, IL-6), and enhances the survival and metastasis of tumor cells (13, 14). Here, BTRC is linked to neoplasm.